ReSTORE (NCT03667690) was a phase 3, randomised, double-blind, non-inferiority trial comparing the efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis. We were delighted to talk with Prof. George Thompson (University of California, Davis, School of Medicine, Sacramento, CA, USA) around the ReSTORE analysis investigating all-cause and attributable mortality with rezafungin. Access […]